title: Endorphins and food intake: kappa opioid receptor agonists and hyperphagia.
abstract: Evidence from studies which utilise either opiate receptor agonists and antagonists strongly indicate a role for endorphinergic mechanisms in the control of feeding responses. Two means by which these compounds may exert an effect on feeding can be singled-out. Firstly, emerging evidence suggests that the process of achieving satiety (terminating a meal, or choice of a commodity) may be accelerated following treatments with opiate receptor antagonists. Secondly, the preference for highly palatable solutions (sweet solutions have received most attention) in two-bottle tests is blocked after injection of opiate receptor antagonists. This finding has been interpreted in terms of the abolition of the reward or incentive quality associated with the particularly attractive flavour. These two mechanisms of action may represent two aspects of a single, fundamental process. Following an introduction to rat urination model of in vivo kappa agonist activity, the consistent effect of several kappa agonists (including the highly selective U-50,488H) to stimulate food consumption is described. Recognising that members of the dynorphin group of endogenous opioid peptides are kappa receptor ligands, some with a high degree of selectivity, and the evidence the dynorphins and neo-endorphins produce hyperphagia in rats is particularly interesting. Such lines of evidence lead to the hypothesis that peptides of the dynorphin group may act endogenously to promote the expression of normal feeding behaviour.
authors.forename: S J
authors.initials: SJ
authors.lastname: Cooper
authors.forename: A
authors.initials: A
authors.lastname: Jackson
authors.forename: T C
authors.initials: TC
authors.lastname: Kirkham
mesh_terms: D019900:3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer; D000700:Analgesics / Q000494:pharmacology; D000818:Animals; D001569:Benzodiazepines / Q000494:pharmacology; D001575:Benzomorphans / Q000494:pharmacology; D002077:Butorphanol / Q000494:pharmacology; D002755:Choice Behavior / Q000187:drug effects; D003496:Cyclazocine / Q000031:analogs & derivatives / Q000494:pharmacology; D004231:Diuresis / Q000187:drug effects; D004326:Drinking / Q000187:drug effects; D004399:Dynorphins / Q000378:metabolism / Q000494:pharmacology; D004435:Eating / Q000187:drug effects*; D004723:Endorphins / Q000502:physiology*; D016314:Ethylketocyclazocine / Q000031:analogs & derivatives; D006801:Humans; D009020:Morphine / Q000494:pharmacology; D009292:Narcotic Antagonists / Q000494:pharmacology; D010620:Phenazocine / Q000031:analogs & derivatives / Q000494:pharmacology; D011759:Pyrrolidines / Q000494:pharmacology; D011957:Receptors, Opioid / Q000502:physiology*; D017473:Receptors, Opioid, kappa; D012528:Satiety Response / Q000187:drug effects
chemical_list: D000700:Analgesics; D001575:Benzomorphans; D004723:Endorphins; D009292:Narcotic Antagonists; D011759:Pyrrolidines; D011957:Receptors, Opioid; D017473:Receptors, Opioid, kappa; D001569:Benzodiazepines; D016314:Ethylketocyclazocine; D019900:3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer; C012395:ketazocine; D004399:Dynorphins; C012134:SK&F 10047; D009020:Morphine; C027248:bremazocine; D010620:Phenazocine; D003496:Cyclazocine; D002077:Butorphanol; C035470:tifluadom